Thoracic Flashcards

1
Q

indications for lung cancer screening (3)

A

1) 55-77
2) current or former smoker within last 15 year
3) 30 pack year history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

IHC marker for lung cancer (2)

A

CK7+, CD20-

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IHC marker for adenocarcinoma (2)

A

TTF-1, Hapsin A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

IHC marker for squamous cell (2)

A

p63+, p40+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prognosis of KRAS mutation (2)

A

Poor OS, does not respond to EGFR-TKIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What to do if resection is positive

A

R1 (microscopic) - resect or RT

R2 (macroscopic) - concurrent chemoRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Indication for adjuvant therapy in lung cancer

A

Stage2A+ after complete resection, often with cisplatin or carboplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment of Stage 3A (N2+)

A

Concurrent chemoRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment of Stage 3A (N1)

A

Surgery + adjuvant chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment of ROS1 mutated metastatic NSCLC

A

ALK inhibitor (crizotinib)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Analysis method for ALK

A

FISH for rearrangements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Evaluation of mediastinal lymph nodes

A

EBUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pemetrexed contraindication

A

Squamous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IOs approved for second line regardless of PDL1 expression

A

Nivolumab and atezolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SCLC limited vs extensive stage

A

Ipsilateral hemithroax or not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Treatment of SCLC

A

Cis/carbo + Etop + radiation if limited stage

17
Q

When to offer PCI in extensive stage SCLC

A

After complete response

18
Q

Staging in SCLC

A

MRI brain with CT C/A/P

19
Q

Most common cytogenetics in SCLC

A

3p deletion

20
Q

Treatment of SCLC after relapse

A

If >90 days with response, reinitiation chemotherapy

If <90 days, other chemo or clinical trial

21
Q

SCLC Encephalomyelitis Ab

22
Q

Good prognosis mesothelioma

A

Epitheloid

23
Q

First line treatment for mesothelioma

A

Carbo/Cis plus pemetrexed

24
Q

Relationship between tobacco smoke and mesothiloma

A

No relationship

25
Treatment of sarcomatoid mesothelioma
chemo or radiation, no surgery
26
Supplementation with pemetrexes
VitB12 and folate
27
Treatment of stage I-II operable mesothelioma
induction chemotherapy
28
Prognostic impact of MG in thymoma presentation
Good prognosis (presents earlier)
29
Test before thymoma resection
Anti-AcH receptor antibody levels
30
Post operative treatment of thymoma or thymic carcinoma
R1: radiation R2: chemoradiation (thymic carcinoma only)
31
Chemotherapy for thymoma
Platinum based (e.g. cyclophosphamide, doxorubicin, cisplatin)
32
Management of suspected resectable thymoma
Resect - don't biopsy
33
Management of MG in thymoma
Control MG first, then resect
34
Management of oligometastatic thymoma
Chemotherapy with surgical re-evaluation
35
Indications for cranial radiation in SCLC
limited stage after CR
36
First line treatment for ALK mutated lung cancer
Alectinib or brigatinib